Conduit Pharmaceuticals Stock Performance
| CDT Stock | 1.11 0.02 1.83% |
The firm shows a Beta (market volatility) of 2.1, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Conduit Pharmaceuticals will likely underperform. At this point, Conduit Pharmaceuticals has a negative expected return of -1.14%. Please make sure to confirm Conduit Pharmaceuticals' potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Conduit Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Conduit Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental indicators remain comparatively stable which may send shares a bit higher in March 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Last Split Factor 1:8 | Last Split Date 2025-10-13 |
1 | What catalysts could drive Conduit Pharmaceuticals Inc. stock higher - July 2025 Trade Ideas Long-Term Growth Portfolio Plans - newser.com | 11/06/2025 |
2 | What catalysts could drive Conduit Pharmaceuticals Inc. stock higher - Earnings Growth Summary Fast Gain Stock Trading Tips - newser.com | 11/12/2025 |
3 | Is Conduit Pharmaceuticals Inc. stock trading at attractive multiples - Weekly Profit Report Fast Moving Market Watchlists - newser.com | 11/19/2025 |
4 | Disposition of 200000 shares by Kuznik Ferdinand of Conduit Pharmaceuticals at 14.25 subject to Rule 16b-3 | 11/25/2025 |
5 | Acquisition by Andrew Regan of 224800 shares of Conduit Pharmaceuticals at 1.79 subject to Rule 16b-3 | 12/08/2025 |
6 | CDT Engages NJS Foresight Bio-Advisory to Support Solid-Form Out-Licensing Strategy | 01/02/2026 |
7 | Should you avoid Conduit Pharmaceuticals Inc. Equity Warrant stock right now - Earnings Growth Summary Risk Adjusted BuySell Alerts - mfd.ru | 01/28/2026 |
| Begin Period Cash Flow | 4.2 M | |
| Total Cashflows From Investing Activities | -43 K | |
| Free Cash Flow | -9.7 M |
Conduit Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 246.00 in Conduit Pharmaceuticals on November 5, 2025 and sell it today you would lose (137.00) from holding Conduit Pharmaceuticals or give up 55.69% of portfolio value over 90 days. Conduit Pharmaceuticals is generating negative expected returns assuming volatility of 6.4361% on return distribution over 90 days investment horizon. In other words, 57% of stocks are less volatile than Conduit, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Conduit Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Conduit Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.11 | 90 days | 1.11 | about 91.39 |
Based on a normal probability distribution, the odds of Conduit Pharmaceuticals to move above the current price in 90 days from now is about 91.39 (This Conduit Pharmaceuticals probability density function shows the probability of Conduit Stock to fall within a particular range of prices over 90 days) .
Conduit Pharmaceuticals Price Density |
| Price |
Predictive Modules for Conduit Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Conduit Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Conduit Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Conduit Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Conduit Pharmaceuticals is not an exception. The market had few large corrections towards the Conduit Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Conduit Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Conduit Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.46 | |
β | Beta against Dow Jones | 2.10 | |
σ | Overall volatility | 0.52 | |
Ir | Information ratio | -0.22 |
Conduit Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Conduit Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Conduit Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Conduit Pharmaceuticals generated a negative expected return over the last 90 days | |
| Conduit Pharmaceuticals has high historical volatility and very poor performance | |
| Conduit Pharmaceuticals may become a speculative penny stock | |
| Conduit Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 922.22 M. Reported Net Loss for the year was (17.8 M) with profit before taxes, overhead, and interest of 0. | |
| Conduit Pharmaceuticals generates negative cash flow from operations | |
| About 26.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Should you avoid Conduit Pharmaceuticals Inc. Equity Warrant stock right now - Earnings Growth Summary Risk Adjusted BuySell Alerts - mfd.ru |
Conduit Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Conduit Stock often depends not only on the future outlook of the current and potential Conduit Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Conduit Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 7225.80 | |
| Cash And Short Term Investments | 554 K |
Conduit Pharmaceuticals Fundamentals Growth
Conduit Stock prices reflect investors' perceptions of the future prospects and financial health of Conduit Pharmaceuticals, and Conduit Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Conduit Stock performance.
| Return On Asset | -2.07 | ||||
| Current Valuation | 63.96 K | ||||
| Shares Outstanding | 1.84 M | ||||
| Price To Book | 0.47 X | ||||
| Revenue | 922.22 M | ||||
| EBITDA | (15.84 M) | ||||
| Net Income | (17.8 M) | ||||
| Total Debt | 7.46 M | ||||
| Book Value Per Share | 3.35 X | ||||
| Cash Flow From Operations | (9.68 M) | ||||
| Earnings Per Share | (176.08) X | ||||
| Market Capitalization | 2.01 M | ||||
| Total Asset | 4.19 M | ||||
| Retained Earnings | (29.1 M) | ||||
| Working Capital | (8.03 M) | ||||
About Conduit Pharmaceuticals Performance
Assessing Conduit Pharmaceuticals' fundamental ratios provides investors with valuable insights into Conduit Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Conduit Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.01 | 0.01 | |
| Return On Capital Employed | 2.12 | 2.23 | |
| Return On Assets | (3.82) | (4.01) | |
| Return On Equity | 2.36 | 2.48 |
Things to note about Conduit Pharmaceuticals performance evaluation
Checking the ongoing alerts about Conduit Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Conduit Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Conduit Pharmaceuticals generated a negative expected return over the last 90 days | |
| Conduit Pharmaceuticals has high historical volatility and very poor performance | |
| Conduit Pharmaceuticals may become a speculative penny stock | |
| Conduit Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 922.22 M. Reported Net Loss for the year was (17.8 M) with profit before taxes, overhead, and interest of 0. | |
| Conduit Pharmaceuticals generates negative cash flow from operations | |
| About 26.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Should you avoid Conduit Pharmaceuticals Inc. Equity Warrant stock right now - Earnings Growth Summary Risk Adjusted BuySell Alerts - mfd.ru |
- Analyzing Conduit Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Conduit Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Conduit Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Conduit Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Conduit Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Conduit Pharmaceuticals' stock. These opinions can provide insight into Conduit Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Conduit Stock Analysis
When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.